3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 1
1
Status
Recruiting
2
Active not recruiting
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
NET
2
Endocrine
2
Sarcoma
1
Lymphoid
1
Gastrointestinal
1
CNS
1
Conditions
Neuroendocrine Tumors
2
Thymus Neoplasms
1
Rhabdomyosarcoma
1
Neuroectodermal Tumors, Primitive, Peripheral
1
Lymphoma
1
Gastro-enteropancreatic neuroendocrine tumor
1
Central Nervous System Neoplasms
1
Interventions
Specimen Handling
321
Magnetic Resonance Spectroscopy
275
pembrolizumab
267
Carboplatin
190
Cyclophosphamide
185
Biopsy
178
Cisplatin
164
Gemcitabine
139
Paclitaxel
137
Bevacizumab
123
fludarabine
122
Nivolumab
117
Radiotherapy
113
Oxaliplatin
94
venetoclax
92
Docetaxel
90
Fluorouracil
88
Capecitabine
88
Dexamethasone
85
Drug Therapy
76
Pemetrexed
75
Rituximab
73
durvalumab
71
Leucovorin
71
Blood Specimen Collection
70
Radiosurgery
69
Standard of Care
67
atezolizumab
64
Doxorubicin
64
Radiation
62
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Recruiting
×
177Lu-octreotide, DOTA(0)-Tyr(3)-
×
90 days
×
Clear all
NCT05918302
2026-05-12
LEVEL
Grupo Espanol de Tumores Neuroendocrinos
Phase 3
Recruiting
170 enrolled
NCT06441331
2026-05-01
KinLET
ITM Solucin GmbH
Phase 1
Recruiting
20 enrolled